124 related articles for article (PubMed ID: 11019422)
21. Effects of high-dose glucose-insulin-potassium on myocardial metabolism after coronary surgery in patients with Type II diabetes.
Szabó Z; Arnqvist H; Håkanson E; Jorfeldt L; Svedjeholm R
Clin Sci (Lond); 2001 Jul; 101(1):37-43. PubMed ID: 11410112
[TBL] [Abstract][Full Text] [Related]
22. [The antioxidant probucol as a regulator of the intensity of free-radical lipid peroxidation processes in the blood of patients with coronary atherosclerosis].
Tikhaze AK; Lankin VZ; Mikhin VP; Revenko VM; Lupanov VP
Ter Arkh; 1997; 69(9):35-41. PubMed ID: 9411823
[TBL] [Abstract][Full Text] [Related]
23. Changes of plasma inflammatory markers after withdrawal of statin therapy in patients with hyperlipidemia.
Li JJ; Li YS; Chu JM; Zhang CY; Wang Y; Huang Y; Chen J; Yuan JQ; Huang YL
Clin Chim Acta; 2006 Apr; 366(1-2):269-73. PubMed ID: 16343471
[TBL] [Abstract][Full Text] [Related]
24. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
Saklamaz A; Comlekci A; Temiz A; Caliskan S; Ceylan C; Alacacioglu A; Yesil S
Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
[TBL] [Abstract][Full Text] [Related]
25. [Effects of a superselective beta1-adrenoblocker nebivolol on the course of coronary heart disease and insulin resistance in patients with diabetes mellitus type 2 after coronary artery bypass grafting].
Tepliakov AT; Kuznetsova AV; Lukinov AV; Levshin AV
Ter Arkh; 2007; 79(12):38-43. PubMed ID: 18220029
[TBL] [Abstract][Full Text] [Related]
26. Swedish adjustable gastric band (SAGB) implanted laparoscopically in the treatment of morbid obesity--the first experience in Poland.
Wylezoł M; Pardela M; Gluck M; Puzio J; Czapla J
Med Sci Monit; 2000; 6(3):441-5. PubMed ID: 11232266
[TBL] [Abstract][Full Text] [Related]
27. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.
Durrington PN; Tuomilehto J; Hamann A; Kallend D; Smith K
Diabetes Res Clin Pract; 2004 May; 64(2):137-51. PubMed ID: 15063607
[TBL] [Abstract][Full Text] [Related]
28. [Indications for and the therapeutic action of hypolipidemic agents in patients with hyperlipoproteinemias].
Goranov I; Naumova R; Kerekovska M; Balabanski L
Vutr Boles; 1987; 26(1):96-101. PubMed ID: 3590738
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of atorvastatin for achieving cholesterol targets after LDL-cholesterol based dose selection in patients with type 2 diabetes.
Ferrer-García JC; Sanchez-Ballester E; Albalat-Galera R; Berzosa-Sanchez M; Herrera-Ballester A
J Cardiovasc Pharmacol Ther; 2008 Sep; 13(3):183-8. PubMed ID: 18635754
[TBL] [Abstract][Full Text] [Related]
30. [Diabetic dyslipidemia and pathogenesis of ischemic heart disease].
Sokolov EI; Perova NV
Kardiologiia; 2003; 43(5):16-20. PubMed ID: 12891233
[TBL] [Abstract][Full Text] [Related]
31. Probucol reduces lysophosphatidylcholines in low-density lipoprotein.
Yoshinari M; Shi AH; Yoshizumi H; Wakisaka M; Iwase M; Fujishima M
Eur J Clin Pharmacol; 2000; 55(11-12):787-92. PubMed ID: 10805055
[TBL] [Abstract][Full Text] [Related]
32. [A comparison of the hypolipidemic action of probucol at doses of 500 and 1000 mg/day in moderate hyperlipoproteinemia].
Tvorogova MG; Lupanov VP; Nuraliev EIu; Zaĭtseva TM; Kukharchuk VV; Titov VN
Ter Arkh; 1998; 70(8):17-21. PubMed ID: 9770737
[TBL] [Abstract][Full Text] [Related]
33. [Free and esterified cholesterol of the skin in atherogenic hyperlipidemias].
Melico-Sylvestre AA; Jacotot B; Buxtorf JC; Beaumont V; Beaumont JL
Paroi Arterielle; 1981; 7(2):59-65. PubMed ID: 7322621
[TBL] [Abstract][Full Text] [Related]
34. [The effect of phenol antioxidants on the development of alloxan diabetes in rats].
Bobyreva LE
Eksp Klin Farmakol; 1997; 60(3):51-3. PubMed ID: 9324400
[TBL] [Abstract][Full Text] [Related]
35. Effect of probucol on triton induced hyperlipidemias in CFY rats.
Krishnamurthy A; Thapar GS; Shridhar DR
Artery; 1985; 13(2):87-94. PubMed ID: 4084069
[TBL] [Abstract][Full Text] [Related]
36. Probucol for treatment of hyperlipidemia in persistent childhood nephrotic syndrome. Report of a prospective uncontrolled multicenter study.
Querfeld U; Kohl B; Fiehn W; Minor T; Michalk D; Schärer K; Müller-Wiefel DE
Pediatr Nephrol; 1999 Jan; 13(1):7-12. PubMed ID: 10100282
[TBL] [Abstract][Full Text] [Related]
37. [Six-month xenical (orlistat) therapy of patients with stable angina pectoris concomitant with obesity and hyperlipidemia].
Naumov VG; Lupanov VP; Dotsenko IuV; Tvorogova MG
Ter Arkh; 2002; 74(1):47-51. PubMed ID: 11878059
[TBL] [Abstract][Full Text] [Related]
38. [Effect of probucol on the concentration of cyclosporin A in patients with nephrotic syndrome].
Wakasugi H; Yoshimoto M; Aoki M; Osawa R; Futami T; Ono T; Muso E; Inui K
Nihon Jinzo Gakkai Shi; 2001 Oct; 43(7):595-9. PubMed ID: 11725557
[TBL] [Abstract][Full Text] [Related]
39. Effects of probucol on the cholesterol content of skin in type II hyperlipoproteinemias.
Beaumont JL; Jacotot B; Buxtorf JC; Silvestre M; Beaumont V
Artery; 1982; 10(1):71-87. PubMed ID: 7092577
[TBL] [Abstract][Full Text] [Related]
40. Probucol and ticlopidine: effect on platelet and monocyte activation markers in hyperlipidemic patients with and without type 2 diabetes.
Nomura S; Takahashi N; Inami N; Kajiura T; Yamada K; Nakamori H; Tsuda N
Atherosclerosis; 2004 Jun; 174(2):329-35. PubMed ID: 15136063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
